Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Agrees to Reduced Sales Schedule from Amphora

SAN FRANCISCO, Dec. 17 - Caliper Technologies said today it would accept a decreased payment schedule from Amphora Discovery for previously negotiated services and products.

 

Payments for data points generated by Amphora using Caliper equipment will drop to a minimum of $1.8 million during the second year of the agreement and $2.2 million paid over time "contingent on Amphora revenue generation" from the $4 million minimum payment originally negotiated due during the second year of the contract, according to Caliper. The company has also agreed to the sale of one Caliper 250 instrument by December 31, 2003in what had originally been an instrument sale pegged for 2002.

 

"While it is undesirable to defer revenue, we believe that a fiscally healthy and viable Amphora best serves Caliper's interests," Caliper CEO Michael Knapp said in a statement. "Amphora has been, and continues to be, a strong advocate and user of our microfluidic LabChip systems."

 

Amphora was spun out from Caliper in 2001 as an independently funded and managed chemical genomics database company. At the time, Caliper owned 28 percent of the company. With a recent financing deal for Amphora, Caliper's equity decreased to less than 15 percent, according to the company. Caliper said it expected further dilution as the company did not plan to make future equity investments in Amphora.

 

At the time of its Amphora spin off, Dan Kisner, then CEO of Caliper, said that Amphora would be a major customer for Caliper's HTS systems. "When fully operational, Amphora has the potential to become the world's largest and most productive high throughput screening center," Kisner said in 2001.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.